Along with chemical, food, and packaging, biopharmaceutical is one of the core businesses of growth within Samyang Group. Samyang Group established Samyang Holdings Biopharmaceuticals in 2011 after its entrance to the biomedical industry in 1995 and has invested over 20% of its income into R&D while securing the expertise within the industry. In 2021, Samyang Holdings went through a merger to absorb Samyang Biopharmaceuticals Corporation for reasons, such as expansion of its influence in the global market, acceleration of global R&D, and preparation of new businesses.
In particular, the anti-cancer drugs Genexol®PM and Nanoxel®PM, adopting the research institute's self-developed technology DDS, show excellent efficacies, such as reduced adverse effects. Our biodegradable sutures are the world's third-developed items of their kind and are exported to 150 clients in 45 countries. Samyang Holdings Biopharmaceuticals is currently constructing a pharmaceutical/bio R&D center on a 1,750-pyeong area in the Pangyo new town's Techno Valley, with an investment of KRW150 billion. This center will be Samyang Holdings Biopharmaceutical 's research hub and will drive it to become a global pharmaceutical company.
Furthermore, in recognition of its R&D investment and technology, Samyang Holdings Biopharmaceuticals was certified as an innovative pharmaceutical company by the Ministry of Health and Welfare in 2012. We endeavor to continuously research on, develop, and sell drugs and medical devices that promote good human health and that enrich the quality of human life. By so doing, we vow to become a company that can be completely trusted by our customers, an innovative company pioneering new values, and a company that fosters talents, and to grow as a global pharmaceutical company.
 |
|
| Head of Samyang Holdings biopharmaceutical division |
Lee Young-Joon |
|---|---|
| Inception | October 2011 |
| Address | #295 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do |
| Tel. | 02-2157-9111 |
| Website | www.samyangbiopharm.com |
